Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Ltd

$PHARMAIDPharmaceuticalsBSE

Pharmaids Pharmaceuticals Ltd (PHARMAID) last traded at ₹31.2, a market capitalisation of ₹110 crore. Over the past 52 weeks the stock has ranged between ₹25.6 and ₹66. Pharmaids Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹4.12 crore and net profit of ₹1.88 crore. Pharmaids Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.

Pharmaids Pharmaceuticals Ltd share price and key metrics

Current price
₹31.2
Market cap
₹110 cr
Book value
₹13.5
ROE
-26.5%
ROCE
-18.5%
Dividend yield
0.00%
52w high / low
66.0/25.6

Metrics as of 25 Aug 2026. Not real time.

Pharmaids Pharmaceuticals Ltd quarterly results

In the quarter ended Jun 2026, sales were ₹4.12 cr, down 38.1% from ₹6.66 cr a year earlier. Net profit turned positive at ₹1.88 cr.

Pharmaids Pharmaceuticals Ltd consolidated quarterly results, figures in ₹ crore
₹ croreSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales5.244.714.776.668.615.437.184.12
Expenses7.657.68.6712.0313.937.947.524.87
Operating profit-2.41-2.89-3.9-5.37-5.32-2.51-0.34-0.75
OPM %-45.99%-61.36%-81.76%-80.63%-61.79%-46.22%-4.74%-18.20%
Other income0.0800.130.043.03-0.320.014.25
Interest0.330.481.011.20.930.720.650.6
Depreciation0.610.640.620.610.470.480.480.49
Profit before tax-3.27-4.01-5.4-7.14-3.69-4.03-1.462.41
Tax %-30.58%-24.94%-11.11%-26.05%-30.62%-34.24%-25.34%22.41%
Net profit-2.27-3.01-4.8-5.27-2.57-2.65-1.091.88
EPS (₹)-0.55-0.55-1.12-1.39-0.71-0.70-0.510.63

Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.

Pharmaids Pharmaceuticals Ltd annual results

Pharmaids Pharmaceuticals Ltd annual profit and loss, figures in ₹ crore
₹ croreMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3.94015.1119.4527.8825.34
Operating profit0.13-9.89-12.35-12.75-13.51-8.92
OPM %3.30%-81.73%-65.55%-48.46%-35.20%
Net profit0.15-7.56-11.85-13.51-11.57-4.43
EPS (₹)0.15-3.52-2.26-3.06-3.32-1.29

TTM is the trailing twelve months to the most recent quarter.

Pharmaids Pharmaceuticals Ltd growth and returns

Compounded Sales Growth
10 Years
%
5 Years
%
3 Years
%
TTM
19%
Compounded Profit Growth
10 Years
%
5 Years
%
3 Years
-50%
TTM
17%
Stock Price CAGR
10 Years
26%
5 Years
19%
3 Years
-9%
1 Year
-51%
Return on Equity
10 Years
%
5 Years
-21%
3 Years
-19%
Last Year
-27%

Pharmaids Pharmaceuticals Ltd shareholding pattern

Promoters held 32.99% at Jun 2026, up from 5.14% at Jun 2025.

Pharmaids Pharmaceuticals Ltd shareholding pattern by quarter, in percent
% heldSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters5.19%5.22%5.22%5.14%32.99%32.99%32.99%32.99%
Public94.81%94.79%94.78%94.87%67.00%67.01%67.00%67.02%
No. of shareholders8,0498,3498,2208,0268,0278,2888,4068,632

As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.

When is Pharmaids Pharmaceuticals Ltd’s AGM?

Pharmaids Pharmaceuticals Ltd’s annual general meeting is scheduled for 11 Sept 2026.

  • AGM37th Annual General Meeting

See the full results calendar for every Indian company reporting in the next 30 days.

Pharmaids Pharmaceuticals Ltd corporate filings

  • Enclosed copies of Newspaper Advertisement published on August 19, 2026 intimating the Notice of 37th Annual General Meeting of the CompanyCompany Updatelow impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Ltd has published a newspaper advertisement regarding the…

    Read the full analysis
  • Annual ReportOtherslow impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Ltd has filed its Annual Report for the financial year 2025-26…

    Read the full analysis
  • Notice of 37th AGM and Annual ReportAGM/EGMlow impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Limited has scheduled its 37th Annual General Meeting for…

    Read the full analysis
  • Newspaper publication of unaudited financial results (standalone & consolidated) for the quarter ended June 30, 2026Company Updatelow impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Limited has published its unaudited financial results for the…

    Read the full analysis
  • Outcome of the Board meeting held today i.e. August 12, 2026Board Meetingmedium impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Limited reported a standalone net profit of 2.13 crore for the…

    Read the full analysis
  • Pharmaids Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....Board Meetinglow impact
    Filing PDF

    Cruxal's analysis: Pharmaids Pharmaceuticals Limited has formally intimated the BSE regarding a Board…

    Read the full analysis

This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.

Track Pharmaids Pharmaceuticals Ltd

Cruxal reads every Pharmaids Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.

Cruxal publishes market data and coverage for information only. Nothing here is investment advice.

Pharmaids Pharmaceuticals Ltd (PHARMAID) Results, Financials & Share Price | Cruxal